Pharmacokinetics and pharmacodynamics of γ-hydroxybutyric acid during tolerance in rats: Effects on extracellular dopamine

Journal of Pharmacology and Experimental Therapeutics

Volumn 320, Issue 3, 2007, Pages 1252-1260

  Raybon, Joseph J ^a   Boje, Kathleen M K ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYBUTYRIC ACID; DOPAMINE;

ACUTE DRUG ADMINISTRATION; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; DOPAMINE BRAIN LEVEL; DOPAMINE METABOLISM; DOPAMINERGIC ACTIVITY; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG EFFECT; DRUG MONITORING; DRUG SENSITIVITY; DRUG TOLERANCE; EXTRACELLULAR MATRIX; IC 50; MALE; MICRODIALYSIS; NONHUMAN; PRIORITY JOURNAL; RAT; SLEEP TIME; STUDENT T TEST;

ANIMALS; BRAIN; DOPAMINE; DRUG TOLERANCE; EXTRACELLULAR FLUID; HYDROXYBUTYRATES; HYPNOTICS AND SEDATIVES; MALE; MICRODIALYSIS; MODELS, BIOLOGICAL; RATS; RATS, SPRAGUE-DAWLEY; SLEEP; TIME FACTORS;

EID: 33847134473     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.106.113886     Document Type: Article

References (34)

1. Bania TC, Ashar T, Press G, and Carey PM (2003) gamma-Hydroxybutyric acid tolerance and withdrawal in a rat model. Acad Emerg Med 10:697-704.
2. Bhattacharya I and Boje KMK (2007) Feasibility of D-glucuronic acid to enhance γ-hydroxybutyric acid metabolism during γ-hydroxybutyric acid toxicity: pharmacokinetic and pharmacodynamic studies. Biopharm Drug Dispos 28:1-11.
3. Bhattacharya I, Raybon JJ, and Boje KMK (2006) Alterations in neuronal transport but not blood-brain barrier transport are observed during gamma-hydroxybutyrate (GHB) sedative/hypnotic tolerance. Pharm Res (NY) 23:2067-2077.
4. Bottiglieri TG, Anderson D, Gibson KM, Froestl W, and Diaz-Arrastia R (2001) Effect of gamma-hydroxybutyrate (GHB) and GABAB receptor antagonists on locomotor activity and brain dopamine metabolism in the rat. Soc Neurosci Abstr 27:971.
5. Bouw MR and Hammarlund-Udenaes M (1998) Methodological aspects of the use of a calibrator in in vivo microdialysis-further development of the retrodialysis method. Pharm Res (NY) 15:1673-1679.
6. Carai MA, Colombo G, Brunetti G, Melis S, Serra S, Vacca G, Mastinu S, Pistuddi AM, Solinas C, Cignarella G, et al. (2001) Role of GABA(B) receptors in the sedative/hypnotic effect of gamma- hydroxybutyric acid. Eur J Pharmacol 428:315-321.
7. Davies B and Morris T (1993) Physiological parameters in laboratory animals and humans. Pharm Res (NY) 10:1093-1095.
8. Dayneka NL, Garg V, and Jusko WJ (1993) Comparison of four basic models of indirect pharmacodynamic responses. J Pharmacokinet Biopharm 21:457-478.
9. Eckermann KA, Koek W, and France CP (2004) Chronic 1,4-butanediol treatment in rats: cross-tolerance to gamma-hydroxybutyrate and (±)-baclofen. Eur J Pharmacol 484:259-262.
10. Feigenbaum JJ and Howard SG (1996) Gamma hydroxybutyrate is not a GABA agonist. Prog Neurobiol 50:1-7.
11. Feigenbaum JJ and Howard SG (1997) Naloxone reverses the inhibitory effect of gamma-hydroxybutyrate on central DA release in vivo in awake animals: a microdialysis study. Neurosci Lett 224:71-74.
12. Fung HL, Haas E, Raybon JJ, Xu J, and Fung SM (2004) Liquid chromatographic-mass spectrometric determination of endogenous δ-hydroxybutyrate concentrations in rat brain and plasma. J Chromatogr B 807:287-291.
13. Gallimberti L, Spella M, Soncini C, and Gessa G (2000) Gamma-hydroxybutyric acid (GHB) in treatment of alcohol and heroin dependence. Alcohol 20:257-262.
14. Gianutsos G and Moore KE (1978) Tolerance to the effects of baclofen and gamma-butyrolactone on locomotor activity and dopaminergic neurons in the mouse. J Pharmacol Exp Ther 207:859-869.
15. Gianutsos G and Suzdak PD (1984) Evidence for down-regulation of GABA receptors following long-term gamma-butyrolactone. Naunyn-Schmiedeberg's Arch Pharmacol 328:62-68.
16. 3H-L- quinuclidinyl benzilate binding and muscarine receptor subsensitivity after chronic gamma-butryolactone treatment. Naunyn-Schmiedeberg's Arch Pharmacol 318:14-18.
17. Howard SG and Feigenbaum JJ (1997) Effect of gamma-hydroxybutyrate on central dopamine release in vivo: a microdialysis study in awake and anesthetized animals. Biochem Pharmacol 53:103-110.
18. Itzhak Y and Ali SF (2002) Repeated administration of gamma-hydroxybutyric acid (GHB) to mice: assessment of the sedative and rewarding effects of GHB. Ann NY Acad Sci 965:451-460.
19. Lettieri JT and Fung HL (1978) Improved pharmacological activity via pro-drug modification: comparative pharmacokinetics of sodium gamma-hydroxybutyrate and gamma-butyrolactone. Res Commun Chem Pathol Pharmacol 22:107-118.
20. Lettieri JT and Fung HL (1979) Dose-dependent pharmacokinetics and hypnotic effects of sodium gamma-hydroxybutyrate in the rat. J Pharmacol Exp Ther 208:7-11.
21. Maitre M (1997) The gamma-hydroxybutyrate signalling system in brain: organization and functional implications. Prog Neurobiol 51:337-361.
22. Martis L and Levy R (1973) Bioavailability calculations for drugs showing simultaneous first-order and capacity-limited elimination kinetics. J Pharmacokinet Pharmacodynam 1:283-294.
23. Morgenroth VH 3rd, Walters JR, and Roth RH (1976) Dopaminergic neurons: alteration in the kinetic properties of tyrosine hydroxylase after cessation of impulse flow. Biochem Pharmacol 25:655-661.
24. Nowycky MC and Roth RH (1979) Chronic gamma-butyrolactone (GBL) treatment: a potential model of dopamine hypoactivity. Naunyn-Schmiedeberg's Arch Pharmacol 309:247-254.
25. Paxinos G and Watson C (1986) The Rat Brain in Stereotaxic Coordinates, Academic Press, Sydney, Australia.
26. Poldrugo F and Addolorato G (1999) The role of gamma-hydroxybutyric acid in the treatment of alcoholism: from animal to clinical studies. Alcohol Alcohol 34:15-24.
27. Roth RH (1975) gamma-Hydroxybutyrate and control of dopaminergic neurons. Psychopharmacol Bull 11:57-58.
28. Roth RH, Doherty JD, and Walters JR (1980) gamma-Hydroxybutyrate: a role in the regulation of central dopaminergic neurons? Brain Res 189:556-560.
29. Roth RH and Giarman NJ (1970) Natural occurrence of gamma-hydroxybutyrate in mammalian brain. Biochem Pharmacol 19:1087-1093.
30. Roth RH and Suhr Y (1970) Mechanism of the gamma-hydroxybutyrate-induced increase in brain dopamine and its relationship to "sleep." Biochem Pharmacol 19:3001-3012.
31. Roth RH, Walters JR, Murrin LC, and Morgenroth VH 3rd (1975) Dopamine neurons: role of impulse flow and presynaptic receptors in the regulation of tyrosine hydroxylase. Psychopharmacol Bull 11:8.
32. Szentistvanyi I, Patlak CS, Ellis RA, and Cserr HF (1984) Drainage of interstitial fluid from different regions of rat brain. Am J Physiol 246:F835-F844.
33. Van Sassenbroeck DK, De Paepe P, Belpaire FM, Boon PA, and Buylaert WA (2003) Tolerance to the hypnotic and electroencephalographic effect of gamma-hydroxybutyrate in the rat: pharmacokinetic and pharmacodynamic aspects. J Pharm Pharmacol 55:609-615.
34. Wong CG, Gibson KM, and Snead OC 3rd (2004) From the street to the brain: neurobiology of the recreational drug gamma-hydroxybutyric acid. Trends Pharmacol Sci 25:29-34.